Clinical trial · Observational
A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer
Contrast Enhanced Ultrasound Using Sonazoid Diagnose Early Stage Endometrial Carcinoma
NCT04961775CI-TRIAL-00052690unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and higher mechanical index, the role of Sonazoid in the early diagnosis of Endometrial carcinoma was explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma Stage I | Endometrial Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Perflubutane Microspheres for Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Diagnostic performance of contrast-enhanced ultrasound in endometrial cancer by Sonazoid.
- timeFrame
- 10 months
- description
- Pathology as a gold standard, to observe the diagnostic performance of Sonazoid in endometrial tumor:a prospective multicenter study based on quantitative and qualitative analysis.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * 1)Patients with Irregular Vaginal bleeding with endometrial thickness is greater than 5mm(Postmenopausal) or10mm (Premenopausal) via transvaginal ultrasound； * 2)Able to perform curettage or other image examination and surgical pathological staging； * 3\) Patients with complete clinical data, pathological test and follow-up data； * 4)Ability to understand, sign informed consent and agree to participate in the investigator. Exclusion Criteria: * 1)Patients without Endometrial carcinoma; * 2)Women during pregnancy and lactation; * 3)Those who are known to be allergic to ultrasound contrast agents; * 4)Patients with arterial-venous (right to left) shunt in the heart or lung or with serious heart diseases or with serious lung diseases; * 5)Any other condition makes patient not eligible for this clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.